Cost-effectiveness of lanthanum carbonate versus sevelamer hydrochloride for the treatment of hyperphosphatemia in patients with end-stage renal disease: a US payer perspective

Authors:

Park H, Rascati KL, Keith MS, Hodgkins P, Smyth M, Goldsmith D and Akehurst R.

Publication Type:

Journal Article

Publication Name:

Value in Health

Citation:

Park H, Rascati KL, Keith MS, Hodgkins P, Smyth M, Goldsmith D and Akehurst R. Cost-effectiveness of lanthanum carbonate versus sevelamer hydrochloride for the treatment of hyperphosphatemia in patients with end-stage renal disease: a US payer perspective. Value Health. 2011;14(8):1002-9.


Link to publication ⟶

⟵ Back to Search Results

By continuing to browse or by clicking "Accept All Cookies" you agree to the storing of first and third-party cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
Cookie Policy
Accept All Cookies
By continuing to browse or by clicking "Accept All Cookies" you agree to the storing of first and third-party cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
Cookie Policy
Accept All Cookies